#### **Hailu Chare Koyra**

College of Medicine and Health Sciences, Department of Pharmacy, Wolaita Soddo University, Soddo, Ethiopia

#### ABSTRACT

Background: Unlike other chronic diseases, people receiving anti-retroviral treatment should have very high levels of adherence (≥ 95%) to achieve durable suppression of viral load; avoid the emergence of drug resistance and clinical failure. Therefore this study was aimed to assess level of adherence and predictors of poor adherence among adult ART patients at Dubbo St. Marry Hospital, Southern Ethiopia. Method: A facility based cross sectional study was conducted to collect data by using structured questionnaires and Moriky's Medication adherence method. Both binary and multiple logistic analyses were performed to examine the influences of different variables on adherence and controlling for potential confounders. Results: Out of 320 patients participated in the study, 214[64%] were females and 162[48.5%] found within the age range of 36-45 years. Among the patients, 32% had poor adherence and comorbidity [AOR=4.004, 95%CI=2.104, 10.830], substance use [AOR=2.360, 95%CI=4.347, 17.915, living alone [AOR=2.262, 95%CI=1.083,5.521] type of regimen [AOR=0.262, 95%CI=0.083,0.521], self-stigma [AOR=2.922, 95%CI=2.446,10.901]and poly-pharmacy [AOR=4.022, 95%CI=1.665,9.730] independently predicted poor adherence. **Conclusion**: Level of medication adherence (68%) among ART patients at Dubbo St. Marry hospital was found to be sub-optimal. The major reasons for not adhering to treatment were forgetting to take medications and fear of adverse effects

### **INTRODUCTION**

The human immunodeficiency virus (HIV) is a retrovirus that infects cells of the immune system, destroying or impairing their functionality. As the infection progresses, the immune system of the infected person becomes weaker, and the patient becomes more susceptible to contract opportunistic diseases. The most advanced stage of HIV infection is acquired immunodeficiency syndrome (AIDS). HIV/AIDS is a public health problem and major development crisis that affects all sectors. It has drastically affected health, economic and social progress reducing life expectancy, deepening poverty, and contributing to and exacerbating food shortages. Today, the estimated number of individuals living with HIV/AIDS worldwide is approximately 33.4 million, including 2.1 million children. The new infection rate is approximately 2.7 million per year, including 430,000 children. Globally, the highest level of HIV/AIDS cases is in sub-Sahara Africa, where approximately 22.4million peoples are infected.<sup>[1,2]</sup> Ethiopia is among the countries most affected by HIV epidemic with an estimated 790,000 HIV positive people. According to the Ethiopian demographic survey, adult HIV prevalence in 2011 was estimated to be 1.5 %. In addition, children under 15 years are also heavily affected and account for over 20% living with HIV in 2011 with prevalence in the urban and rural population 7.7% and 0.9% respectively. In the country, ART was first offered in July 2003 through 12 government hospitals on a co-payment basis. In early 2005, 211,000 men, women and children needed ART but only 16,400 were receiving it.<sup>[3,4]</sup>

Adherence is taking the correct dose of medications, on schedule, and following dietary instructions. Unlike other chronic conditions, very high levels of adherence (>95%) are required for ART to be effective for long term and to prevent the emergence of resistant viral strains. Poor adherence is

Keywords: Adherence, antiretroviral therapy, hospital, ethiopia

# Correspondence:

Hailu Chare Koyra, College of Medicine and Health Sciences, Department of Pharmacy, Wolaita Soddo University, Soddo, Ethiopia. **E-mail:** charehailu@gmail.com, or hailu.chare@wsu.edu.et



linked to the development of drug resistance, higher mortality rates, lower rates of increase in CD4 cell count, lower rates of undetectable viral load, lower therapeutic success and increased hospital days.<sup>[5,6]</sup> The importance of ART is that it shortens illness duration, improves quality of life and survival of PLWHA through reduction of viral load and increasing the level of CD4 cells. However, lack of adherence to ART is a major challenge to AIDS care.<sup>[7]</sup>

#### The conceptual frame work

The conceptual framework of this study is based on literature findings that showed factors which have been cited as reasons for non-adherence include forgetting, travel, fear of disclosure, shortage of pills, difficult schedules, lack of access and privacy [Figure 1]. Other consistent factors for poor adherence include patient reported symptoms, stress, lack of social support, substance use, regimen complexity, self-efficacy for medication taking and depression.<sup>[8-11]</sup>

#### Significance of the study

Little is known about the factors affecting ART adherence and the magnitude of ART adherence in Wolaita Zone, especially Areka town. Therefore, the objective of this study is to assess level of adherence and predictors of poor adherence among HIV/AIDS patients receiving Antiretroviral Therapy at Dubbo

For reprints contact: invoice@jbclinpharm.org

**Cite this article as:** Koyra HC. Prevalence of Type 2 Diabetes Associated Complications ion Kurdistan Region Iraq. J Basic Clin Pharma 2018;9:115-121.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.



**Figure 1:** Conceptual frame work of ART adherence and predictors of poor adherence among HIV/AIDS patients at Dubbo St. Marry Hospital Southern, Ethiopia, 2014

St. Marry Hospital. The issue of ARV adherence among HIV/ AIDS in Ethiopia and in study area is important. This study determined the status and magnitude of adherence and factors that affect adherence in Dubbo St. Marry hospital among patients who follow ARV therapy, since there is no adequate research conducted on adherence and factors that affect it in the study area. The finding of this study will help as baseline data for those who are interested in caring out for further research. In addition this study will create the awareness in society about ARV adherence.

# METHODOLOGY

# Study area and period

The study was conducted in Dubbo St. Marry Hospital, Areka town, SNNPR, Ethiopia. Areka town is located about 382 km south from Addis Ababa, about 205 km from Hawassa, the capital of the SNNPR region. The hospital is rapidly expanding in terms of services it provides and infrastructures. It provides multidimensional aspects of care to clients who need health service. There are 6 specialty units and many follow-up services for both pediatric and adult patients. The study was conducted from July to August 2016.

# Study design

An institutional based cross sectional descriptive study was conducted.

### Source population

All patients on ART follow up in Dubbo St. Marry Hospital.

### **Study population**

Patients on ART during the study period and who fulfill inclusion criteria.

### Inclusion criteria for interviewees

Age above 18 years and those on ARV treatment for at least 3 months or more.

#### Exclusion criteria

Critically ill, unwilling and patients with documented mental illness

### Sample size and sampling technique

The study was designed to collect data from all adult patients who were on their chronic care follow up, and willing to participate in the study as depicted in the figure below.

### Study variables

Medication adherence to ART, Socio-demographic, Sociocultural factors, Disease related variables, Medication and facility related variables, Patients related variables

# Data collection technique

Data was collected through structured questionnaire which was translated to the local language for patient interview to collect information on socio-demographic, socio-economic and information on medication adherence.

### Data process and analysis

Completeness of the data was checked every day and entered and cleaned using EPI-data version 3.1 and exported to SPSS. To examine the influences of different variables on medication adherence and controlling for potential confounders, both binary and multiple logistic analyses were performed. Independent variables having p-value <0.25 in the bivariate logistic regression analysis were entered into multivariable logistic regression analysis in order to control confounding effect. P-value of <0.05% was considered significant in the final model.

### Medication adherence assessment tool

Non-adherence was identified by using validated Morisky Medication Adherence Scale (MMAS) which consists of 8 items with a dichotomous response (yes/no) with questions asking the patient to respond "yes" or "no" to items 1-7 and a 5 point Likert response for the last item. A positive response indicates a problem with adherence. Therefore, higher scores indicate that a patient is least-adherent to medications. The total score for each patient is the summation of the scores in each item.<sup>[12-14]</sup>

# **Operational definition**

Non-adherence: if the patient scores  $\geq$  3 in Morisky Medication Score.

Comorbidity- any documented disease condition for which the patient is taking treatment.

Adverse effect- any documented harmful and undesired effect resulting from a medication.

Highly active antiretroviral therapy (HAART)- the name given to treatment regimens meant to aggressively suppress viral replication and progress of HIV disease.

Resistance- a documented reduction in a pathogen's sensitively to a particular drug

Poly-pharmacy: patients those taking  $\geq$  five drugs for at least one months period.

Substance use: consumption of any one of chat, cigarette and alcohol.

# **Ethical considerations**

An official letter from the College sent to the hospital for study cooperation. Data was collected after permission was asked from the study subjects following a brief discussion with the patients on ART about the purpose and public health importance of the study. Data was collected only from those who were willing to participate. To maintain confidentiality respondents were informed that their data used anonymously.

# RESULTS

# Socio-demographic and socio-economic characteristics

One hundred and sixty seven eligible respondents were selected for the study at Dubbo St. Marry Hospital. Among those subjects, 320 participated in the study [Figure 1]. Out of this, 214 [67%] females and 106 [33%] males participated in this study. From the respondents, 184 [57.5%] were married; and 162 [50.6%], 68[21.25%], 50[15.6%], of them were Wolaita, Hadiya, and Kambata, by ethnicity respectively. As to the religion of respondents, 150 [46.9%], 110[33.4%] and 60[18.7%], were Protestant, Orthodox and Muslim, respectively. The majority of the participants had primary school complete 85.0% followed by holders of diploma and above 35.0%. As to occupation of the participants, majority of ART patients were found to be government employee 110(34.4%) and merchants 70(22%) of the respondents, majority were found within the age range of 36-45 years, 162[50.6%] followed by age range of 26-35, 104 [32.5%]. This is in agreement with scientifically proven impact of HIV/AIDS on the productive segment of the population in a given country. As to the living conditions of respondents, majority reported as they either live alone or together with their family, 128(40%) and 120(37.5) respectively [Table 1]. It was also found that majority of respondents stayed 6-10 years, 112(35%) followed by 1-5 years 68(21.3%) since they started their ART [Table 2].

Only 30(18.7%) of the respondents reported that they did not suffer from stigma due to their HIV status. But, majority 78(48.7%) of respondents said that they avoid friends or relatives due to stigma during ARV treatment. Surprisingly, 113(70.7%) of respondents reported that they use traditional methods of treatment in addition to HAART. Among respondents, 106 (66.2%) reported as they perceive HAART is effective to reduce their viral load and improve life. Among the respondents, about 10% reported that their sex-partners were sero-negative (discordant) and 8.2% have not known their status vet. Majority, 135(84.4%) of ART patients reported that they do not know about adverse effects of ARV drugs [Table 3]. As depicted in the figure below, this study also collected data on substance abuse and found that over all prevalence of substance use was found to be 69(43%). Among these, majority 55(79.7%) reported that they were using both alcohol and cigarette followed by drinking alcohol only 41(59.4%) to relieve pain and depression associated with the disease [Figure 2]. More than half, 182(56.8%) of the respondents, were with documented co-morbidities. Among 
 Table 1: Basic socio-demographic attributes of HIV patients at Dubbo

 St.Marry Hospital 2016

Variables	frequency	Percent
Ethnicity of respondents		
Wolaita	162	50.6
Hadiya	68	21.3
Kambata	50	15.6
Others	40	12.5
Educational Status		
Illiterate	16	5
Grade 1-8	160	50
Grade 9-12	32	10
Diploma and above	112	35
Marital Status		
Single	24	7.5
Married	184	57.5
Divorced	56	17.5
Widowed	40	12.5
Separated(not confirmed legally)	16	5.0
Occupational Status		
Government employee	110	34.4
Merchant	70	22
Driver	36	11.2
Farmers	60	18.7
Police men	20	6.2
Others	24	7.5
Sex		
Female	214	67
Male	106	33
Place of residence		
Urban	122	38.2
Rural	188	61.8
Monthly income		
Below 500	70	21.8
500-1000	58	18.4
1000-1500	142	44.2
Above 1500	50	15.6
Age of respondents		
19.25	14	4.4
26-35	104	32.5
36-45	162	50.6
Above 45	40	12.5
Living condition		
Alone	100	40
With family	128	40 27 r
College/university	120	3/.5 10
Support centers	32 19	10
Other *	10	5.5 7

those, it was found that the most common disease conditions other than HIV were TB 28.5%, fungal infections 21% and Depression 17.5% [Table 4].

# Medication adherence and perceived reasons for poor adherence (Based on MMAS-8)

According to MMAS, 200(60%) of respondents had good medication adherence (MMAS<3) and 134(40%) found to have poor medication adherence (MMAS  $\geq$  3). The patients were also asked to mention reasons or barriers for not-adhering to ARV drugs. The major reasons for not adhering to treatment were forgetting to take medications 44 (43%) followed by fear of adverse effects 30(29%)[Figure 3]. Figure 3 Perceived reasons for poor-adherence reported by HIV patients at Dubbo St.Marry Hospital, Southern Ethiopia, 2016(N=102)

**Table 2:** Disease and patients related variables among HIV patients at DubboSt.Marry Hospital , southern ethiopia, 2016 (N=320)

Variables	Frequency	Percent		
Duration of ART(length of time of ART in years)				
Below one year	40	12.5		
1-5 years	68	21.3		
6-10 years	112	35		
11-15 years	56	17.5		
Above 15 years	44	13.7		
Sero-status of sex partner				
Positive	260	81.2		
Negative	34	10.6		
Not known	26	8.2		
Previous history of hospitalization	after ART			
Yes	104	32.5		
No	216	67.5		
Experiencing stigma				
From others	156	48.7		
Self –stigma	104	32.6		
No stigma	60	18.7		
Average CD4 level of the last three	consecutive visits	(in cells/m³)		
Below 100	32	10		
100-500	88	27.5		
501-1000	154	48		
Above 1000	46	14.5		
Use of treatments other than HAA	RT			
Traditional medicine	60	18.7		
Religious methods	166	52		
Only HAART	94	29.3		
Knowledge on adverse effects of A	RV drugs			
l know	50	15.6		
l don't know	270	84.4		
Level of adherence				
MMAS <sup>*</sup> <3(poor)	102	32		
MMAS $\geq$ 3(good)	218	68		
Perception towards effectiveness of	of HAART			
Effective	212	66.2		
In effective	38	11.8		
Not sure	70	22		

\*Morisky Medication Adherence Score

Table 3: Distribution of comorbidities among HIV patients at Dubbo St.Marry hospital, southern Ethiopia, 2016 (N=320)

Other disease conditions	Frequency	Percent	
Comorbid conditions			
Yes	182	54.5	
No	138	45.5	
Tuberculosis	52	28.5	
Fungal infections	38	21	
Depression	32	17.5	
Heart Failure	28	15.4	
UTI	20	11	
Others	12	6.6	

# Health care facility and health care providers influence on adherence to ARV treatment

All of respondents [100%] said that they were able to follow their ARV treatment, they know the importance of following the course of treatment strictly, they were counseled especially before they were started on ARV treatment, privacy was maintained during consultations and agreed that it was important for HIVpatients to be counseled as they continue with ARV treatment



Figure 2: Schematic representation of sampling procedure during the period of data collection

Table 4: Medication related variables of HIV/AIDS patients at Dubbo St. Marry hospital, southern ethiopia, 2016, (N=320)

Variables	Frequency	percent
Types of 1 <sup>st</sup> line ART regimens(N=254)		
AZT+3TC+EFZ	70	27.5
AZT+3TC+NVP	20	8
TDF+3TC+EFZ	102	40.2
TDF+3TC+NVP	40	15.7
ABC+3TC+AZT	22	8.6
Types of 2 <sup>nd</sup> line ART regimens(N=66)		
AZT +3TC +LPV/r	28	42.4
AZT +ABC+LPV/r	22	33.3
TDF+3TC+LPV/r	16	24.3
Number of pills taken per day		
Less than three	112	35
Three-five	126	39.4
More than five drugs	82	25.6
Frequency of doses per day		
Once	80	25
2 times	144	45
3times	48	15
More than 3 times	48	15
Other concurrent medications		
Anti TB drugs	52	16.2
CPT⁺	192	60
CV drugs	30	9.4
Contraceptives	36	11.2
Others	10	3.2

Cotrimoxazole prophylactic therapy

because it helped to improve ART adherence. However, majority of respondents 84.4 % did not know about the side effects and interactions of ARV drugs.

As depicted in table-3 above, distributions of ART drug regimens used by the HIV/AIDs patients at Dubbo St. Marry Hospital, more than 56% of the participants were taking TDF+3TC+EFZ among a first line regimens. The most commonly used concurrent medications were CPT 192(60%) followed by anti-TB drugs 52(16.2%). It was found that the quarter of HIV/AIDs patients at Dubbo St. Marry Hospital were taking more than five drugs 82(25.6%) per day(poly-pharmacy) and about half of the respondents responded that they were taking their medications in BID bases 72(45%).



**Figure 3:** Prevalence of substance abuse among study participant, Dubbo St.Marry Hospital, Southern Ethiopia, 2016 N=334

# Predictors of poor medication adherence among ART patients

Bivariate analysis showed that there was significant association between medication adherence and age range of 21-30 years, illiteracy, monthly income, duration ART, self-stigma, comorbidity, living condition, substance use, male gender, number daily doses, types of ARV drug regimens, occupational status, daily dose, and previous history of hospitalization. Multivariable logistic regression analysis was done to identify independent predictors of medication adherence among the study participants. Accordingly, it was found that presence of comorbidity, substance abuse, living alone, AZT based drug regimen, experiencing self-stigma and number of pills per day independently predicted the likelihood of poor medication adherence among HIV/AIDS patients. Subjects living with diseases other than HIV/AIDS were found to be four times more likely to have poor medication adherence than those without comorbidity [AOR=4.004, 95%CI=2.104,10.830] with p-value=000. Using substances like alcohol doubled the likelihood of poor adherence among patients [AOR=2.360, 95%CI=4.347, 17.915] at p-value of 0.020. Similarly, patients

Table 5: Predictors of poor medication adherence among patients on ART at Dubbo St. Marry hospital, southern Ethiopia, 2016 (N=334)

$\begin{array}{ c c c c c c } & Por (%) & God (%) & \\ Comorbidity & & & & & & & & & & & & & & & & & & &$	Predictors	Predictors Medication adherence CO		COR	AOR [95% C.I.]	p-values	
Comorbidity         No(Ref)         8/2(25.6)20(6.2)         10(31.2)         1.662         4.004[2.104.10.80]         0.000*           Gender         Emale(Ref)         62(19.4)         56(20.6)         2.150         2.377[0.041-11.553]         0.071           Substance use         Yes         0.0(40.3)22(19)         58(12)         0.237         0.420*         0.020*           Living condition         Yes         0.0(40.3)22(19)         58(12)         0.422         2.360[4.347.17.915]         0.020*           Living condition         Yes         0.0(40.3)22(19)         60(29)         4.82         2.360[9.337(0.041-11.553]         0.020*           Living condition         Yes         0.0(40.3)22(19)         60(29)         4.82         2.360[9.33.471.7.915]         0.020*           Living condition         Yes         0.0(47.5)         1.046         2.262[1.083-55.21]         0.007*           Support centers         12(3.75)         1.28         1.00(20.155.367]         0.171           Support centers         12(3.75)         1.4(4.3)         2.401         0.500(0.966-7.114]         0.403           TpF+3TC+FE72(Ref)         413(5.6)         52(19.4)         1.655         3.112[2.767-14.302]         0.016*           AZT+3TC+FE72 AZT+3TC+FE72 (Ref		<b>Poor</b> (%)	Good (%)				
Yes No(Ref)         82(25.6)20(6.2)         10(31.2) 118(37)         1.62         4.004[2.104-10.830]         0.000*           Gender	Comorbidity						
No(Ref)         DELEXIJONOLIZI         118(37)         1           Gender         Female(Ref) Male         52(19,4) 80(12.5)         152(47.5) 66(20.6)         1         1           Substance use         Yes No (Ref)         80(40.3)22(19)         58(12) 160(29)         4.822         2.360[4.347-17.915]         0.020*           Living condition         Yes No (Ref)         38(11.8)         82(25.6)         1         0         0.007*           Living condition         24(7.5)         104(32.5)         0.146         2.262[1.083-55.21]         0.007*           College/university         20(3.75)         6[1.8)         2.401         0.580[0.966-7.114]         0.403           Other         8(2.5)         14(4.3)         1.144         0.279[0.922-18.006]         0.201           TDF+3TC+EFZ (Ref)         24(34.4)         78(21.8)         1         1           AZT+3TC+EFZ (Ref)         24(34.4)         78(21.8)         1.112(2.767-14.302]         0.016*           AZT+3TC+EFZ (Ref)         24(34.4)         78(21.8)         1.114         0.409(333-6.685]         0.800           AZT+3TC+EFZ (Ref)         18(5.6)         2.118         5.022[0.437-5.292]         0.301           AZT+3TC+EFZ (Ref)         103(1)         1.055         3.5	Yes	82(25 6)20(6 2)	100(31.2)	1.062	4.004[2.104-10.830]	0.000*	
Gender         Female(Ref) Male         62(19.4) 80(12.5)         152(47.5) 66(20.6)         1.10         1           Substance use         Yes No (Ref)         80(40.3)22(19)         58(12) 160(29)         4.822         2.360[4.347-17.915] 1         0.020*           Living condition             0.020*         1           With family (Ref)         38(11.8)         82(25.6)         1         0.020*         0.007*           College/university         20(6.25)         12(3.75)         0.146         2.262[1.083-5.521]         0.007*           Support centers         21(23.75)         12(8)         1.40         0.580[0.906-7.114]         0.403           Other         82(25.5)         14(4.3)         1.144         0.279[0.922-18.006]         0.201           TDF+3TC+EFZ (Ref)         24(34.4)         78(21.8)         1         1         0.006*         0.800           TDF+3TC+EFZ (Ref)         24(34.4)         78(21.8)         1         1.44         0.499(0.833-6.655)         0.800           TDF+3TC+EFZ AZT+3TC+NVP         18(5.6)         52(19.4)         1.655         3.112[2.767-14.302]         0.016*           AZT+3TC+LFZ (Ref)         24(34.4)         78(21.8)         1.655         3.112[0.277-	No(Ref)	02(23.0)20(0.2)	118(37)		1		
Female(Ref) Male         62(19.4) 80(12.5)         12(47.5) 66(20.6)         1           Substance use         Yes No (Ref)         58(12) 80(40.3)22(19)         2.150         2.377(0.041-11.553)         0.020*           Living condition         1         0.020*         1         0.020*         1           Living condition         20(62.5)         12(3.75)         0.4822         2.360[4.347-17.915]         0.007*           College/university         20(62.5)         12(3.75)         1.28         1.002[0.155-3.671]         0.171           Support centers         12(3.75)         6(1.8)         2.401         0.580[0.966-7.114]         0.403           Other         20(52.5)         12(3.75)         1.28         1.002[0.155-3.671]         0.171           Support centers         12(3.75)         6(1.8)         2.401         0.580[0.966-7.114]         0.403           Other         20(52.5)         14(4.3)         3.441         0.4079[0.922-18.006]         0.001*           TDF+3TC+EFZ(Ref)         24(34.4)         78(21.8)         1         5.022[0.437-5.292]         0.301           AZT+3TC+AVP         61(1.8)         14(4.3)         3.441         0.409[0.833-6.85]         0.800           AZT+3TC+AZT         20(6.2)         2.016	Gender		450(47.5)				
Male         80(12.5)         66(2.06) 2.150         2.377[0.041-11.553]         0.071           Substance use No (Ref)         Yes No (Ref)         80(40.3)22(19) 10         58(12) 10         4.822         2.360[4.347-17.915] 1         0.020* 1           Living condition           1         0.020* 1         0.007*           Alone         24(7.5)         104(32.5)         0.146         2.262[1.083-5.521]         0.007*           College/university         20(6.25)         12(3.75)         1.28         1.002[0.155-3.671]         0.413           Support centers         12(3.75)         61.8         2.401         0.580(0.966-7.14]         0.403           Other         8(2.5)         14(4.3)         1.144         0.279(0.922-18.006]         0.201           Types of regimen         1         1         1         0.403         0.443         0.499(0.833-6.685]         0.800           TDF+3TC+HEZ AZT+STC+HVP         18(5.6)         52(19.4)         1.655         3.112[2.67-14.302]         0.016*           AZT+3TC+HVV         10(3.1)         14(4.3)         0.493         1.006[6.022-23.114]         1.351           AZT+ABC+LPV/r         10(3.1)         18(5.6)         1.001         2.112[0.277+1.887]         0.707 </td <td>Female(Ref)</td> <td>62(19.4)</td> <td>152(47.5)</td> <td></td> <td>1</td> <td></td>	Female(Ref)	62(19.4)	152(47.5)		1		
Substance use No (Ref)         Yes No (Ref)         S8(12) 80(40.3)22(19)         58(12) 10(29)         4.822         2.360[4.347-17.915] 1         0.020*           Living condition               0.020*         1           Living condition              0.000*         1           College/university         20(6.25)         12(3.75)         1.28         1.002[0.155-3.671]         0.171           Support centers         12(3.75)         61.8         2.401         0.580(0.966-7.114]         0.403           Other         8(2.5)         14(4.3)         1.144         0.279[0.922-18.006]         0.201           Types of regimen         1         1         0.403         0.414         0.409[0.833-6.685]         0.800           TDF+3TC+EFZ(Ref)         18(5.6)         52(19.4)         1.655         3.112[2.767-14.302]         0.016*           AZT+3TC+EFZ(Ref)         18(5.6)         52(19.4)         1.655         3.112[2.767-14.302]         0.016*           AZT+3TC+HV/P         0(61.2)         20(62.2)         2118         5.022[0.437-5.529]         0.301           AZT+3TC+HV/r         10(3.1)         1655         3.950[1.331-1.	Male	80(12.5)	66(20.6)	2.150	2.377[0.041-11.553]	0.071	
Substance use         58(12) No (Ref)         58(12) 80(40.3)22(19)         4.822         2.360[4.347-17.915] 1         0.020* 1           Living condition	C						
Tes No (Ref)         80(40.3)22(19)         160(29)         4.822         2.300(4.547-(7)315)         0.020*           Living condition         1         1         1         1           Living condition         24(7.5)         104(32.5)         0.146         2.262(1.083-5.521)         0.007*           College/university         20(6.25)         12(3.75)         6(1.8)         2.401         0.580(0.966-7.114)         0.403           Other         8(2.5)         14(4.3)         1.144         0.279(0.922-18.006]         0.201           Types of regimen         24(34.4)         78(21.8)         1         1           AZT+3TC+EFZ AZT+3TC+NVP         18(5.6)         52(1.94)         1.655         3.112(2.767-14.302)         0.006*           TDF+3TC+FEZ AZT+3TC+NVP         18(5.6)         52(1.94)         1.655         3.112(2.767-14.302)         0.016*           AZT+3TC+EFZ AZT+3TC+NVP         6(1.8)         14(4.3)         0.993         1.006(6.022-23.114)         1.351           AZT+3TC+EFZ AZT+3TC+NVP         6(1.8)         14(4.3)         0.993         1.006(6.022-23.114)         1.351           AZT+3TC+EFZ AZT         2(06.2)         2016.2)         2.118         5.022[0.477-1.887]         0.707           AZT+3TC+EFZ AZT	Substance use		58(12)	4 0 2 2	2 260[4 247 17 015]	0.020*	
Living condition With family (Ref) 38(11.8) 82(25.6) 1 Alone 24(7.5) 104(32.5) 0.146 2.262[1.083-5.521] 0.007* College/university 20(6.25) 12(3.75) 1.28 1.002[0.155-3.671] 0.171 Support centers 12(3.75) 61(4.3) 2.401 0.580[0.667.114] 0.403 Other 8(2.5) 14(4.3) 1.144 0.279[0.922-18.006] 0.201 Types of regimen TDF+3TC+EFZ(Ref) 24(34.4) 78(21.8) 1 TDF+3TC+EFZ(Ref) 18(5.6) 52(19.4) 1.655 3.112[2.767-14.302] 0.016* AZT+3TC+EFZ AZT+3TC+NVP 6(1.8) 14(4.3) 3.441 0.409[0.833-6.685] 0.800 TDF+3TC+HZT 27(-4ZT) 20(6.2) 20(6.2) 2.118 5.022[0.437-5.292] 0.301 ABC+3TC+AZT 82(2.5) 14(4.3) 0.993 1.006[6.022-23.114] 1.351 AZT+3TC+LPV/r 10(3.1) 18(5.6) 1.001 2.112[0.277-1.887] 0.707 AZT+ABC+LPV/r 10(3.1) 18(5.6) 1.001 2.112[0.277-1.887] 0.707 TDF+3TC+LPV/r 6(1.8) 10(3.1) 4.055 3.950[1.331-11.261] 0.023* TDF+3TC+LPV/r 6(1.8) 10(3.1) 4.055 3.950[1.331-11.261] 0.023* History of hospitalization Yes 32(10) 72(22.5) 0.511[0.203-0.885] 0.11* No(Ref) 50(46.8) 66(20.6) 1.011 1 Experiencing stigma From others 56(17.5) 100(31.2) 1.403 1.772[0.698-17.229] 0.201 Self-stigma 64(20) 40(12.5) 5.884 2.922[2.446-10.901] 0.004* No stigma (Ref) 52(16.2) 60(18.7) 1 Number of pills/day Less than three(Ref) 52(16.2) 60(18.7) 1 Three -five 72(22.5) 54(16.8) 1.667 1.003[2.119-65.002] 0.089 More than five drugs 24(7.5) 58(18.3 4.7710 4.022[1.665-9.730] 0.000*	Tes No (Bof)	80(40.3)22(19)	160(29)	4.022	2.500[4.547-17.915]	0.020**	
Living condition         With family (Ref)         38(11.8)         22(2.5)         1           Alone         24(7.5)         104(32.5)         0.146         2.262[1.083-5.521]         0.007*           College/university         20(6.25)         12(3.75)         1.28         1.002[0.155-3.671]         0.171           Support centers         12(3.75)         6(1.8)         2.401         0.580[0.966-7.114]         0.403           Other         8(2.5)         14(4.3)         1.44         0.279[0.922-18.006]         0.201           TpF+3TC+EFZ (Ref)         24(34.4)         78(21.8)         1         1         4403           AZT+3TC+EFZ AZT+3TC+NVP         18(5.6)         52(19.4)         1.655         3.112[2.767-14.302]         0.016*           AZT+3TC+EFZ AZT+3TC+NVP         18(5.6)         52(19.4)         1.655         3.112[2.767-14.302]         0.018*           AZT+3TC+EFZ AZT+ATC+NVP         18(5.6)         52(10.2)         2.118         5.022[0.437-5.292]         0.301           AZT+3TC+LPV/r         18(5.6)         1.011         2.112[0.277-1.837]         0.707           AZT+3TC+LPV/r         10(3.1)         8.05         1.003         2.112[0.277-1.837]         0.707           AZT+3TC+LPV/r         10(3.1)         10	NO (REI)				I		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Living condition						
Alone         24(7.5)         104(32.5)         0.146         2.262[1.083-5.521]         0.007*           College/university         20(6.25)         12(3.75)         1.28         1.002[0.155-3.671]         0.171           Support centers         12(3.75)         6(1.8)         2.401         0.580[0.966-7.114]         0.403           Other         8(2.5)         14(4.3)         1.144         0.207[0.922-18.006]         0.017           TDF+3TC+EFZ(Ref)         24(3.4,4)         78(21.8)         1         1           AZT+3TC+EFZ AT+3TC+NVP         6(1.8)         52(19.4)         1.655         3.112[2.767-14.302]         0.016*           ABC+3TC+AZT         20(6.2)         20(6.2)         2.118         5.022[0.437-5.292]         0.301           ABC+3TC+AZT         82.5)         14(4.3)         0.993         1.006[6.022-23.114]         1.351           AZT+3TC+LPV/r         10(3.1)         18(5.6)         1.001         1.212[0.277-1.887]         0.707           AZT+3TC+LPV/r         10(3.1)         18(5.6)         1.001         2.121[0.277-1.887]         0.707           AZT+3TC+LPV/r         10(3.1)         18(5.6)         1.001         2.121[0.277-1.887]         0.707           AZT+3TC+LPV/r         12(3.75)         1	With family (Ref)	38(11.8)	82(25.6)		1		
College/university         20(6.25)         12(3.75)         1.28         1.002[0.155-3.671]         0.171           Support centers         12(3.75)         6(1.8)         2.401         0.580[0.966-7.114]         0.403           Other         8         114(4.3)         1.144         0.279[0.922-18.006]         0.201           Types of regimen         24(34.4)         78(21.8)         1         1         0.409[0.833-6.685]         0.800           AZT+3TC+EFZ AZT+3TC+NVP         18(5.6)         52(19.4)         1.655         3.112[2.767-14.302]         0.016*           AZT+3TC+EFZ AZT+3TC+NVP         6(1.8)         14(4.3)         3.441         0.409[0.833-6.685]         0.800           TDF+3TC+AZT         20(6.2)         20(6.2)         2.118         5.022[0.437-5.292]         0.301           ABC+3TC+AZT         82.5)         14(4.3)         0.993         1.006[6.022-23.114]         1.351           AZT+3TC+LPV/r         10(3.1)         18(5.6)         1.001         2.112[0.277-1.887]         0.707           AZT+ABC+LPV/r         10(3.1)         18(5.6)         1.001         2.112[0.277-1.887]         0.707           MCRef)         150(46.8)         66(20.6)         1.011         1         1         1	Alone	24(7.5)	104(32.5)	0.146	2.262[1.083-5.521]	0.007*	
Support centers Other         12(3.75)         6(1.8)         2.401         0.580(0.966-7.114]         0.403           Types of regimen         1         14(4.3)         1.144         0.279[0.922-18.006]         0.201           Types of regimen         1         1         1         0.006*         0.006*           AZT+3TC+EFZ AZT+3TC+NVP         18(5.6)         52(19.4)         1.655         3.112[2.767-14.302]         0.016*           AZT+3TC+EFZ AZT+3TC+NVP         6(1.8)         14(4.3)         3.441         0.409[0.833-6.685]         0.800           ABC+3TC+AZT         20(6.2)         20(6.2)         2.118         5.022[0.437-5.292]         0.301           AZT+3TC+IPV/r         10(3.1)         18(5.6)         1.001         2.112[0.277-1.887]         0.707           AZT+3TC+IPV/r         10(3.1)         18(5.6)         1.001         2.112[0.0277-1.887]         0.707           AZT+3TC+IPV/r         10(3.1)         18(5.6)         1.001         2.112[0.0277-1.887]         0.707           MCRef         1         1.093[2.744-22.114]         0.023*         0.011*           bistory of hospitalization         1         1         0.023*         0.011*           No(Ref)         150(46.8)         66(20.6)         1.011 <td>College/university</td> <td>20(6.25)</td> <td>12(3.75)</td> <td>1.28</td> <td>1.002[0.155-3.671]</td> <td>0.171</td>	College/university	20(6.25)	12(3.75)	1.28	1.002[0.155-3.671]	0.171	
Other         8(2.5)         14(4.3)         1.144         0.279[0.922-18.006]         0.201           Types of regimen         TDF+3TC+EFZ(Ref)         24(34.4)         78(21.8)         1         1           AZT+3TC+EFZ AXT+3TC+NVP         18(5.6)         52(19.4)         1.655         3.112[2.767-14.302]         0.016*           AZT+3TC+EFZ AXT+3TC+NVP         6(1.8)         14(4.3)         3.441         0.409[0.833-6.685]         0.800           TDF+3TC+LPV/r         20(6.2)         20(6.2)         2.118         5.022[0.437-5.292]         0.301           AZT+3TC+LPV/r         8(2.5)         14(4.3)         0.993         1.006[6.022-23.114]         1.351           AZT+ABC+LPV/r         10(3.1)         18(5.6)         1.001         2.112[0.277.1.887]         0.707           AZT+ABC+LPV/r         10(3.1)         18(5.6)         1.001         2.112[0.277.1.887]         0.023*           MEStory of hospitalization         10(3.1)         5.108         1.093[2.744-22.114]         0.023*           No(Ref)         150(46.8)         6(6.0)         1.011         1         1           From others         56(17.5)         100(31.2)         1.772[0.698-17.229]         0.201           No(Ref)         36(11.2)         24(7.5)	Support centers	12(3.75)	6(1.8)	2.401	0.580[0.966-7.114]	0.403	
Types of regimen         24(34.4)         78(21.8)         1           TDF+3TC+EFZ(Ref)         18(5.6)         52(19.4)         1.655         3.112[2.767-14.302]         0.016*           AZT+3TC+EFZ AZT+3TC+NVP         6(1.8)         14(4.3)         3.441         0.409[0.833-6.685]         0.800           TDF+3TC+AZT         20(6.2)         20(6.2)         2.118         5.022[0.437-5.292]         0.301           AZT+3TC+LPV/r         8(2.5)         14(4.3)         0.993         1.006(6.022-23.114]         1.351           AZT+ABC+LPV/r         10(3.1)         18(5.6)         1.001         2.112[0.277-1.887]         0.707           AZT+ABC+LPV/r         12(3.75)         10(3.1)         4.055         3.950[1.331-11.261]         0.023*           TDF+3TC+LPV/r         10(3.1)         5.108         1.093[2.744-22.114]         0.023*           history of hospitalization         Yes         32(10)         72(2.5)         0.511[0.203-0.885]         0.011*           No(Ref)         150(46.8)         60(2.0)         1.01         1         1           From others         56(17.5)         100(31.2)         1.772[0.698-17.229]         0.201           Self-stigma         64(2.0)         40(12.5)         5.884         2.922[2.446-10.901]	Other	8(2.5)	14(4.3)	1.144	0.279[0.922-18.006]	0.201	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Types of regimen						
AZT+3TC+EFZ AZT+3TC+NVP       18(5.6)       52(19.4)       1.655       3.112[2./6/-14.302]       0.016*         TDF+3TC+NVP       6(1.8)       14(4.3)       3.441       0.409[0.833-6.685]       0.800         ABC+3TC+AZT       20(6.2)       20(6.2)       2.118       5.022[0.437-5.292]       0.301         ABC+3TC+LPV/r       10(3.1)       18(5.6)       1.001       2.112[0.277-1.887]       0.707         AZT+ABC+LPV/r       10(3.1)       18(5.6)       1.001       2.112[0.277-1.887]       0.707         AZT+3TC+LPV/r       12(3.75)       10(3.1)       4.055       3.950[1.331-11.261]       0.023*         TDF+3TC+LPV/r       6(1.8)       10(3.1)       5.108       1.093[2.744-22.114]       0.923*         history of hospitalization       Ves       32(10)       72(22.5)       0.511[0.203-0.885]       0.011*         No(Ref)       150(46.8)       66(20.6)       1.011       1       1         Experiencing stigma       64(20)       40(12.5)       5.884       2.922[2.446-10.901]       0.004*         No stigma (Ref)       36(11.2)       24(7.5)       5.884       2.922[2.446-10.901]       0.004*         Less than three(Ref)       52(16.2)       60(18.7)       1       1       1 <td>TDF+3TC+EFZ(Ref)</td> <td>24(34.4)</td> <td>78(21.8)</td> <td></td> <td>1</td> <td></td>	TDF+3TC+EFZ(Ref)	24(34.4)	78(21.8)		1		
TDF+3TC+NVP         6(1.8)         14(4.3)         3.441         0.409[0.833-6.685]         0.800           ABC+3TC+AZT         20(6.2)         20(6.2)         2.118         5.022[0.437-5.292]         0.301           AZT+3TC+LPV/r         8(2.5)         14(4.3)         0.993         1.006[6.022-23.114]         1.351           AZT+ABC+LPV/r         10(3.1)         18(5.6)         1.001         2.112[0.277-1.887]         0.707           AZT+ABC+LPV/r         12(3.75)         10(3.1)         4.055         3.950[1.331-11.261]         0.023*           history of hospitalization         6(1.8)         10(3.1)         5.108         1.093[2.744-22.114]         1           history of hospitalization         Yes         32(10)         72(22.5)         0.511[0.203-0.885]         0.011*           No(Ref)         150(46.8)         66(20.6)         1.011         1         1           Experiencing stigma         64(20)         40(12.5)         5.884         2.922[2.446-10.901]         0.004*           No stigma (Ref)         32(16.2)         24(7.5)         5.884         2.922[2.446-10.901]         0.004*           Less than three(Ref)         22(16.2)         60(18.7)         1         1         1           Number of pills/day	AZT+3TC+EFZ AZT+3TC+NVP	18(5.6)	52(19.4)	1.655	3.112[2.767-14.302]	0.016*	
ABC+3TC+AZT         20(6.2)         20(6.2)         2.118         5.022[0.437-5.292]         0.301           AZT+3TC+LPV/r         8(2.5)         14(4.3)         0.993         1.006[6.022-23.114]         1.351           AZT+ABC+LPV/r         10(3.1)         18(5.6)         1.001         2.112[0.277-1.887]         0.707           DF+3TC+LPV/r         12(3.75)         10(3.1)         4.055         3.950[1.331-11.261]         0.023*           history of hospitalization         (61.8)         10(3.1)         5.08         1.093[2.744-22.114]         0.011*           Mo(Ref)         150(46.8)         66(20.6)         1.011         1         0.011*           Experiencing stigma         From others         56(17.5)         100(31.2)         1.772[0.698-17.229]         0.201           Self-stigma         64(20)         40(12.5)         5.884         2.922[2.446-10.901]         0.004*           No stigma (Ref)         36(11.2)         24(7.5)         1         1         1           Number of pills/day         Less than three(Ref)         52(16.2)         60(18.7)         1         1           More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730]         0.009*	TDF+3TC+NVP	6(1.8)	14(4.3)	3.441	0.409[0.833-6.685]	0.800	
AZT+3TC+LPV/r       8(2.5)       14(4.3)       0.993       1.006[6.022-23.114]       1.351         AZT+ABC+LPV/r       10(3.1)       18(5.6)       1.001       2.112[0.277-1.887]       0.707         TDF+3TC+LPV/r       12(3.75)       10(3.1)       4.055       3.950[1.331-11.261]       0.023*         history of hospitalization       61.8)       10(3.1)       5.108       1.093[2.744-22.114]       0.021*         history of hospitalization       72(22.5)       0.511[0.203-0.885]       0.011*         Ves       32(10)       72(22.5)       0.511[0.203-0.885]       0.011*         No(Ref)       150(46.8)       66(20.6)       1.011       1         Experiencing stigma       64(20)       40(12.5)       5.884       2.922[2.446-10.901]       0.004*         No stigma (Ref)       36(11.2)       24(7.5)       5.884       2.922[2.446-10.901]       0.004*         Number of pills/day       1       1       1       1       1         Less than three(Ref)       52(16.2)       60(18.7)       1       1       1         More than five drugs       24(7.5)       58(18.3)       4.710       4.022[1.665-9.730]       0.000*	ABC+3TC+AZT	20(6.2)	20(6.2)	2.118	5.022[0.437-5.292]	0.301	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	AZT+3TC+LPV/r	8(2.5)	14(4.3)	0.993	1.006[6.022-23.114]	1.351	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	AZT+ABC+LPV/r	10(3.1)	18(5.6)	1.001	2.112[0.277-1.887]	0./0/	
6(1.8)       10(3.1)       5.108       1.093[2.744-22.114]         history of hospitalization       Yes       32(10)       72(22.5)       0.511[0.203-0.885]       0.011*         No(Ref)       150(46.8)       66(20.6)       1.011       1       1         Experiencing stigma       66(20.6)       1.011       1       1         Experiencing stigma       56(17.5)       100(31.2)       1.403       2.922[2.446-10.901]       0.004*         Self-stigma       64(20)       40(12.5)       5.884       2.922[2.446-10.901]       0.004*         No stigma (Ref)       36(11.2)       24(7.5)       1       1       1         Number of pills/day       Less than three(Ref)       52(16.2)       60(18.7)       1       1         More than five drugs       24(7.5)       58(18.3)       4.710       4.022[1.665-9.730]       0.000*	TDF+3TC+LPV/r	12(3./5)	10(3.1)	4.055	3.950[1.331-11.261]	0.023*	
history of hospitalization       Yes       32(10)       72(22.5)       0.511[0.203-0.885]       0.011*         No(Ref)       150(46.8)       66(20.6)       1.011       1       1         Experiencing stigma       56(17.5)       100(31.2)       1.403       2.72[0.698-17.229]       0.201         Self-stigma       64(20)       40(12.5)       5.884       2.922[2.446-10.901]       0.004*         No stigma (Ref)       36(11.2)       24(7.5)       1       1       1         Number of pills/day       Less than three(Ref)       52(16.2)       60(18.7)       1       1         More than five drugs       24(7.5)       58(18.3)       4.710       4.022[1.665-9.730]       0.000*		6(1.8)	10(3.1)	5.108	1.093[2./44-22.114]		
Yes         32(10)         72(22.5)         0.511[0.203-0.885]         0.011*           No(Ref)         150(46.8)         66(20.6)         1.011         1           Experiencing stigma         66(20.6)         1.011         1           From others         56(17.5)         100(31.2)         1.403         2.922[2.446-10.901]         0.004*           Self-stigma         64(20)         40(12.5)         5.884         2.922[2.446-10.901]         0.004*           No stigma (Ref)         36(11.2)         24(7.5)         1         1         1           Number of pills/day         Less than three(Ref)         52(16.2)         60(18.7)         1         1           More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730]         0.000*	history of hospitalization						
No(Ref)         150(46.8)         66(20.6)         1.011         1           Experiencing stigma         From others         56(17.5)         100(31.2)         1.403         2.72[0.698-17.229]         0. 201           Self-stigma         64(20)         40(12.5)         5.884         2.922[2.446-10.901]         0.004*           No stigma (Ref)         36(11.2)         24(7.5)         1         1           Number of pills/day         Less than three(Ref)         52(16.2)         60(18.7)         1         1           More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730]         0.000*	Yes	32(10)	72(22.5)		0.511[0.203-0.885]	0.011*	
Experiencing stigma         56(17.5)         100(31.2)         1.403         1.772[0.698-17.229]         0. 201           Self-stigma         64(20)         40(12.5)         5.884         2.922[2.446-10.901]         0.004*           No stigma (Ref)         36(11.2)         24(7.5)         1         1         1           Number of pills/day         Less than three(Ref)         52(16.2)         60(18.7)         1         1           Three – five         72(22.5)         54(16.8)         1.667         1.003[2.119-65.002]         0.089           More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730]         0.000*	No(Ref)	150(46.8)	66(20.6)	1.011	1		
From others         56(17.5)         100(31.2)         1.403         1.772[0.698-17.229]         0. 201           Self-stigma         64(20)         40(12.5)         5.884         2.922[2.446-10.901]         0.004*           No stigma (Ref)         36(11.2)         24(7.5)         1         1         1           Number of pills/day         Less than three(Ref)         52(16.2)         60(18.7)         1         1           Three – five         72(22.5)         54(16.8)         1.667         1.003[2.119-65.002]         0.089           More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730]         0.000*	Experiencing stigma						
Self-stigma No stigma (Ref)         64(20) 36(11.2)         40(12.5) 24(7.5)         1.4403 5.884         2.922[2.446-10.901]         0.004*           Number of pills/day         1         1         1         1         1           Number of pills/day         52(16.2)         60(18.7)         1         1         1           Three – five         72(22.5)         54(16.8)         1.667         1.003[2.119-65.002]         0.089           More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730]         0.000*	From others	56(17.5)	100(31.2)	1 /03	1.772[0.698-17.229]	0. 201	
No stigma (Ref)         36(11.2)         24(7.5)         5.004         1           Number of pills/day         Less than three(Ref)         52(16.2)         60(18.7)         1           Three – five         72(22.5)         54(16.8)         1.667         1.003[2.119-65.002]         0.089           More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730]         0.000*	Self-stigma	64(20)	40(12.5)	5 884	2.922[2.446-10.901]	0.004*	
Number of pills/day         52(16.2)         60(18.7)         1           Less than three(Ref)         52(25.5)         54(16.8)         1.667         1.003[2.119-65.002]         0.089           More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730]         0.000*	No stigma (Ref)	36(11.2)	24(7.5)	5.004	1		
Less than three(Ref)         52(16.2)         60(18.7)         1           Three – five         72(22.5)         54(16.8)         1.667         1.003[2.119-65.002]         0.089           More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730] <b>0.000*</b>	Number of pills/day						
Three – five         72(22.5)         54(16.8)         1.667         1.003[2.119-65.002]         0.089           More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730] <b>0.000*</b>	Less than three(Ref)	52(16.2)	60(18.7)		1		
More than five drugs         24(7.5)         58(18.3)         4.710         4.022[1.665-9.730]         0.000*	Three –five	72(22.5)	54(16.8)	1.667	1.003[2.119-65.002]	0.089	
	More than five drugs	24(7.5)	58(18.3)	4.710	4.022[1.665-9.730]	0.000*	

\*Statistically significant

living alone, and taking AZT+3TC+EFZ based regimen were found to be less likely adherent to their medication [AOR=0.262, 95%CI=0.083,0.521], and [AOR=0.112, 95%CI=0.067,0.302] respectively. It was also found that patients experiencing self-stigma were about three times more likely to have poor medication adherence as compared to those who did not [AOR=2.922, 95%CI=[2.446-10.901] at p-value<0.05. But, respondents with previous history of hospitalization while on ART were found to have better adherence to their medications than those who have not been hospitalized [AOR=0.511, 95%CI=0.203, 0.885] at p-value <0.05 [Table 5]. Finally, the study has found that taking more than five drugs per day has increased the likelihood of poor medication adherence for about four times among ART patients at Dubbo St. Marry Hospital [AOR=4.022, 95%CI=1.665,9.730] at p-value=000.

# DISCUSSION

Unlike other chronic conditions, very high levels of adherence (>95%) are required for ART to be effective for long term and to prevent the emergence of resistant viral strains. Poor adherence to ART can cause drug resistance, higher mortality rates, lower rates of increase in CD4 cell count, lower rates of undetectable viral load, lower therapeutic success, emergence of OIs and increased hospitalization.<sup>[5,6]</sup> As literatures revealed, it is difficult to measure adherence in the outpatient setting with absolute precision and accuracy as it may result in recall biases due to its dependence on patients' self-report. Therefore, researchers use variety of adherence assessment methods of which none is considered to be a gold standard. The current study used a validated Morisky Medication Adherence assessment method with the aim of assessing level of adherence and predictors of poor adherence among HIV/AIDS patients receiving Antiretroviral Therapy at Dubbo St. Marry Hospital.

Socio-demographically, out of 320 HIV/AIDS patients included in the study, 67% of were females and those found within the age range of mid-thirties to mid-forties (50.6%). This is consistent with Talam et al. study in Kenya.<sup>[15]</sup> This is a clear indication that the disease affects a productive segment of the population in the country. This study has found that level of medication adherence among ART patients at Dubbo St. Marry hospital was 60%. This is consistent with myriad of studies conducted in most developed countries which documented that HAART adherence rates range from 40% to 75%. This finding is higher than Talam et al. study in Kenya<sup>[15]</sup>, which showed that 43.2% of respondents adhered to their medication. But, it is lower than the study done in north-west Ethiopia which shows that the adherence level of patients was 80.9%.<sup>[16]</sup> The discrepancy of findings could partly be explained as the difference in methods used to assess adherence, income and difference in health care facility.

The most common reasons reported for poor adherence were simple forgetting to take medications (43%), fear of adverse effects (29%) followed by feeling hopelessness. This finding is in agreement with several studies conducted previously.<sup>[17-19]</sup> As corroborated by many past studies too majority of ART patients report forgetting as the most common reason for their poor adherence. This could be due to the effect of the disease on thinking ability of the patients or resultant depression. In

Journal of Basic and Clinical Pharmacy, Vol 9, Issue 1, Jan-Mar, 2018

the current study, 84.4% of ART patients reported that they do not know adverse effects resulted from ARV drugs. This could have a contribution to poor adherence as fear of toxicity for the drugs was found to be the second common reason of nonadherence especially AZT based drug regimens were found to be significantly associated with poor adherence.

Poor medication adherence among patients with comorbidity and those taking more than five pills per day was a fourfold in the current study. Similarly, use of substances, loneness, AZT based regimen, and self-stigma independently predicted poor medication adherence. This finding has consistency with study done in Australia which showed that alcohol consumption has significantly been associated with poor adherence.<sup>[20]</sup> Sankar *et al.* also found that loneliness is a key factor that influence adherence to ART.<sup>[21]</sup>

Similarly, many other authors reported that the existence of significant relationships between several factors, non-adherence to combination therapy can result from forgetting, lack of motivation, and intolerance of side effects. As reported in the study conducted in southwest Ethiopia at the ART unit of Jimma University specialized hospital, depression was associated with non-adherence. Adherence was common among those who had social support systems. More than 75% of the respondents reported that they missed doses due to forgetting, feeling sick or ill, being busy, and running out of medications.<sup>[12]</sup> A study conducted in the southern part of Ethiopia at Yirgalem Hospital found that the main reasons for non-adherence included being busy or simply forgetting, changes in daily routine, and being away from home.<sup>[13]</sup>

In this study, there was no association between variables like gender, marital status, age and income which were found to be predictors of poor adherence in previous studies. The reason could be difference in adherence assessment methods, study design, socio-demography of the population etc. However, patients with previous history of hospitalization while on ART were found to be more adherent to their medication as compared to others. The reason might be partly explained as further investigation and assessment of patients' condition and adherence status by physicians, increased awareness about medication adherence and change in attitude they got from health professionals at the time of hospitalization could result in improved medication taking behaviors.

### Limitations of the study

Chance of recall bias in adherence assessment as it was based on respondents' self-report, absence of causality assessment for ADR, chart review may result in missing of some data.

#### CONCLUSIONS

Level of adherence (60%) among patients on ART at Dubbo St. Marry hospital was found to be sub-optimal but comparable to other developing countries. Forgetting and fear of side effects were commonly reported as reasons for non-adherence. Statistically, poly-pharmacy, living alone, feeling self-stigma, AZT-based drug regimen and comorbidity independently predicted poor adherence.

#### **Recommendations**

Based on the above findings, the following recommendations are forwarded

Strategies should be designed to enhance patients' awareness regarding ways to improve adherence, adverse effects and effectiveness of HAART.

Refreshment trainings and clinical updates should be provided to heath care providers.

Continuous community health education programs should be provided to avoid stigma and increasing social support to PLWHA.

#### Acknowledgement

The author is grateful to W/ro Birtukan Ermias, Blen Hailu and Grace Hailu, for their unreserved support throughout the study. Finally, Dubbo St. Marry hospital staffs and the study participants are also acknowledged for their cooperation during data collection.

#### REFERENCES

- United Nations Program on HIV/AIDS. AIDS Epidemic Update 2009. http://data.unaids.org/ pub/report/2009/jc1700\_epi\_update\_2009\_en.pdf.
- The Federal Democratic Republic of Ethiopia. Guidelines for the implementation of antiretroviral therapy in Ethiopia, Addis Ababa, Ethiopia 2005.
- Ministry of Health. Disease Prevention and Control Department, Single Point HIV Prevalence Estimate 2007.
- Panos Global AIDS Program: Antiretroviral drugs for all. Obstacles to access to HIV/AIDS: treatment Lessons from Ethiopia, Haiti, India, Nepal and Zambia 2006.
- Hogan D, Salomon J. Prevention and treatment of HIV/AIDS in resource limited settings. Bulletin of WHOM 2005;83:2.
- Paterson DL, Swindells S, Mohr J, Brester M, Vergis E, Squire C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.

- Carballo E, Suarez CC, Carrera I. Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Research 2004;13: 587-99.
- Tadios Y, Davey G. Retroviral drug adherence and its correlates in Addis Ababa, Ethiopia; Ethiop Med J 2006;44:237-44.
- Miftah A. Antiretroviral Treatment Adherence and Its Determinants among People Living With HIV/AIDS on Highly Active Antiretroviral Therapy at Two Hospitals in Oromiya Regional State; Addis Ababa, Ethiopia 2007.
- Kasumu LO, Balogun MR. Knowledge and attitude towards ART and adherence Pattern of HIV patients in Nigeria 2014;10:6-12.
- Ayalew M. Assessment of Adherence to Antiretroviral Therapy among HIV-infected persons in Addis Ababa and Debreziet at the ministry of national Defense force hospitals; Addis Ababa, Ethiopia 2005.
- Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV infected persons: a prospective study in Southwest Ethiopia; BMC Public Health 2008;8:265.
- Endrias Markos, Alemayehu Worku, Gail Davey. Ethiop J.Health Dev, Adherence to ART in PLWHA at Yirgalem Hospital, South Ethiopia 2008;20:234-8.
- Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67–74.
- NC Talam P, Gatongi J, Rotich S, Kimaiyo. Factors Affecting Ntiretroviral Drug Adherence Among Hiv/Aids Adult Patients Attending HIV/AIDs Clinic At Moi Teaching and Referral Hospital, Eldoret, Kenya; East African J. of Public Health 2008;5.
- Tsega B, Srikanth BA, Shewamene Z. Determinants of non-adherence to antiretroviral therapy in adult hospitalized patients, Northwest Ethiopia. Patient Prefer Adherence 2015;9:373-80.
- 17. World Health Organization, From Access to Adherence: The Challenges of Antiretroviral Treatment- Studies from Botswana, Tanzania and Uganda. Geneva 2008. Online, Available: file://E:\annathobias@yahoo.com\Js13400e.5[1].htm.
- Wroth TH, Pathman MD. Primary Medication Adherence in a Rural Population: The Role of the Patient-Physician Relationship and Satisfaction with Care. University of Carolina. JABFM 2006;19:5.
- Simpson RJ. Challenges for Improving Medicine Adherence. J.of the Ame. Med. Associat 2006;296.
- 20. McAllister J. Antiretroviral Drug Therapy for HIV-Infection: Developing an Adherence Framework. Management HIV. Sydney: Australia 2006.
- Sankar A, Golin C, Simoni JM, Luborsky M, Pearson C. How Qualitative Methods Contribute to Understanding Combination Antiretroviral Therapy Adherence 2006; 43:854-S68.